Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001181594
Ethics application status
Approved
Date submitted
20/08/2024
Date registered
27/09/2024
Date last updated
27/09/2024
Date data sharing statement initially provided
27/09/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
A prospective study for use of a retinal sealant (PYK-2101) for participants undergoing vitrectomy for retinal detachment repair
Query!
Scientific title
A prospective surgical study evaluating the safety and tolerability of a novel, biodegradable retinal sealant (PYK-2101) following vitrectomy for retinal detachment repair
Query!
Secondary ID [1]
312687
0
Nil
Query!
Universal Trial Number (UTN)
N/A
Query!
Trial acronym
N/A
Query!
Linked study record
N/A
Query!
Health condition
Health condition(s) or problem(s) studied:
Retinal Detachment
334683
0
Query!
Vitrectomy
334684
0
Query!
Retinal Surgery
334686
0
Query!
Condition category
Condition code
Eye
331254
331254
0
0
Query!
Diseases / disorders of the eye
Query!
Surgery
331255
331255
0
0
Query!
Surgical techniques
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
PYK-2101 is a novel retinal sealant to be utilized in conjunction with vitrectomy in the repair of retinal detachment. PYK-2101 is an investigational product, a hydrogel, provided by Pykus Therapeutics to the selected investigators (ophthalmic surgeons) for use in the surgical suite and is a single use (single surgery) intervention.. During the vitrectomy (typically about a 30 minute procedure), after all retinal breaks have been treated, the investigational product is prepared and is then administered via a cannula similar to what is already used routinely in retina surgery. The surgeon will apply a focused, micro delivery of gel to the site of retinal breaks so that all of the retinal breaks are completely covered which allows for a minimal amount of product. The application process is less than 5 minutes of the 30 minute procedure. This is a single use/dose product. a maximum volume administered will be 0.2mL. The surgeon and investigational team will follow the procedure as described in the protocol and Instructions For Use. They will be trained in use prior to site activation and prior to participant enrollment which is minimally one week in advance of treatment. This is a single one hour training provided by members of the Pykus Therapeutics team. The training is a combination of live in-in person, and video provided training. The site has had previous experience in the preparation and application of hydrogel, however this is a new formulation. The device is anticipated to biodegrade at approximately 6 weeks.. Compliance is assessed via objective imaging during the treatment (surgical video) and post-operative day one via Slit-lamp assessement with dilated funduscopy; wide-field color fundus photography, Macular SD-OCT. .
Query!
Intervention code [1]
329216
0
Treatment: Surgery
Query!
Intervention code [2]
329469
0
Treatment: Other
Query!
Comparator / control treatment
No control group or similar
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
339028
0
Rate of Adverse events occuring for all participants. Anticipated adverse events specific to use of the device include; inflammation; elevated Intra Ocular Pressure (IOP); recurrent retinal detachment.
Query!
Assessment method [1]
339028
0
At each visit, participants will be assessed for changes from their baseline assessments. The assessments include:
Visual Acuity , Full Ophthalmic exam, wide-field color fundus photography, and Macular Spectral-Domain Optical Coherence Tomography (Macular SD-OCT), and Best Corrected Visual Acuity (BCVA).
Query!
Timepoint [1]
339028
0
At each visit, participants will be assessed for changes from their baseline assessments (screening visit, day of procedure, post-procedure day 1, week 1, week 3, week 4.5, week 6 , and week 12.
Visual Acuity , Full Ophthamic exam, wide-field color fundus photography, and Macular SD-OCT will be performed at screening visit, post-procedure day 1, week 1, week 3, week 6 , and week 12. BCVA will be assessed at screening visit and week 12.
Query!
Primary outcome [2]
339029
0
Visual acuity changes from baseline
Query!
Assessment method [2]
339029
0
Visual acuity will be assessed using prior prescription, if any, and using Best Corrected Visual Acuity as measured with the ETDRS (Early Treatment Diabetic Retinopathy) chart
Query!
Timepoint [2]
339029
0
Visual acuity will be assessed at screening, post-procedure day 1, week 1, week 3, week 6 and week 12
Query!
Primary outcome [3]
339030
0
Lens changes from baseline:
Query!
Assessment method [3]
339030
0
Full ophthalmic exam will assess lens status. This includes a slit lamp exam, IOP assessment, and dilated funduscopy.
Query!
Timepoint [3]
339030
0
Lens status will be assessed at screening, post-procedure day 1, week 1, week 3, week 4.5, week 6, and week 12.
Query!
Secondary outcome [1]
438310
0
Incidence of recurrent retinal detachment
Query!
Assessment method [1]
438310
0
Wide-field color fundus photograph and Macular SD-OCT
Query!
Timepoint [1]
438310
0
The Wide-field color fundus photograph and Macular SD-OCT is assessed at screening, post-procedure day 1, week 1, week 3, week 6, and week 12
Query!
Secondary outcome [2]
438311
0
Changes to Quality of Life related to post surgical physical positioning requirements assessed utilizing the 5Q-5D-5L assessment questionnaire at at screening, post-procedure day 1, week 1, week 3, week 6, and week 12
Query!
Assessment method [2]
438311
0
The 5Q-5D-5L questionnaire
Query!
Timepoint [2]
438311
0
The 5Q-5D-5L assessment questionnaire is implemented at screening, post-procedure day 1, week 1, week 3, week 6, and week 12 visits.
Query!
Secondary outcome [3]
439598
0
intra-ocular pressure (IOP) change from baseline. This is an additional primary outcome.
Query!
Assessment method [3]
439598
0
IOP will be assess via tonometry
Query!
Timepoint [3]
439598
0
IOP will be assessed at screening, post-procedure day 1, week 1, week 3, week 4.5, week 6, and week 12.
Query!
Secondary outcome [4]
439599
0
Cataract progression (if phakic) or degree of IOL (Intraocular Lens) changes (if pseudophakic). This is an additional primary outcome.
Query!
Assessment method [4]
439599
0
Cataract progression will be assessed via a Visual acuity exam, and a full ophthalmic exam including slit lamp exam, IOP assessment, and dilated funduscopy.
Query!
Timepoint [4]
439599
0
IOP will be assessed at screening, post-procedure day 1, week 1, week 3, week 4.5, week 6, and week 12.
Query!
Eligibility
Key inclusion criteria
1. Age 18 or older of any gender
2. Undergoing vitrectomy for repair of primary rhegmatogenous retinal detachment with no more than 6 retinal breaks in total
a. Primary detachment refers to rhegmatogenous detachment that occurs in a previously uninvolved eye without any complicating factors (e.g., proliferative vitreoretinopathy or penetrating trauma)
3. Phakic or pseudophakic
4. Willing to participate in the study as evidenced by signing of an informed consent document
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Pregnancy or breastfeeding
2. Known allergy to Hyaluronic Acid (HA); or Polyethylene Glycol (PEG)
3. Aphakic
4. Any prior history of uveitis, or other inflammatory or rheumatologic disease
5. A history of neovascularization of the iris (NVI) or the angle (NVA)
6. Known contraindication to using topical glaucoma drops or oral acetazolamide
7. Any condition or circumstance that, in the opinion of the surgeon investigator, would compromise the safety of the subject or the quality of study data
8. Participation in any clinical study of an investigational product within 30 days prior to enrollment, or any other planned eye surgery during the course of the study
Intraoperative Exiting Criteria
If any of the following are observed prior to attempted use of the investigational device, the subject will not receive the device and will be exited from the study:
1. Inability to flatten the retina
2. Presence of proliferative vitreoretinopathy (PVR), need to create a retinectomy, or retinal breaks larger than one clock hour
3. No more than 6 retinal breaks in total are permitted; breaks in any quadrant are permitted
4. Significant intraoperative retinal and/or choroidal bleeding
5. Any condition, intraoperative complication, or circumstance that in the opinion of the surgeon investigator, would compromise the safety of the subject, or the quality/interpretation of study data
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety
Query!
Statistical methods / analysis
The sample size of 10 completed subjects is commonly used in early-stage clinical development pilot studies of safety and tolerability and was not chosen to provide a specified amount of inferential statistical power.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
27/09/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
28/02/2025
Query!
Actual
Query!
Date of last data collection
Anticipated
28/05/2025
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
TAS
Query!
Recruitment hospital [1]
26903
0
Hobart Eye Surgeons - Hobart
Query!
Recruitment postcode(s) [1]
42961
0
7000 - Hobart
Query!
Funding & Sponsors
Funding source category [1]
317119
0
Commercial sector/Industry
Query!
Name [1]
317119
0
Pykus Australia Pty Ltd
Query!
Address [1]
317119
0
Query!
Country [1]
317119
0
Australia
Query!
Funding source category [2]
317121
0
Commercial sector/Industry
Query!
Name [2]
317121
0
Pykus Therapeutics Inc
Query!
Address [2]
317121
0
Query!
Country [2]
317121
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pykus Therapeutics Inc.
Query!
Address
Query!
Country
United States Minor Outlying Islands
Query!
Secondary sponsor category [1]
319378
0
Commercial sector/Industry
Query!
Name [1]
319378
0
Pykus Australia Pty Ltd
Query!
Address [1]
319378
0
Query!
Country [1]
319378
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
315873
0
Bellberry Human Research Ethics Committee L
Query!
Ethics committee address [1]
315873
0
https://bellberry.com.au/
Query!
Ethics committee country [1]
315873
0
Australia
Query!
Date submitted for ethics approval [1]
315873
0
17/07/2024
Query!
Approval date [1]
315873
0
19/08/2024
Query!
Ethics approval number [1]
315873
0
Query!
Summary
Brief summary
The purpose of this research project is to provide a new alternative to currently approved methods of sealing retinal breaks for participants that are undergoing repair of retinal detachments. The name of the investigational product in this study is PYK-2101. PYK-2101 will be injected during surgery as a retinal sealant to tears/breaks in the retina. Use of the investigational product will prevent subjects from having to remain in a face down position for a number of days, will not limit their ability for air travel for a period of time, nor require an additional surgery to remove the tamponade and may have improved visual clarity as compared to other methods.
Query!
Trial website
N/A
Query!
Trial related presentations / publications
Query!
Public notes
N/A
Query!
Contacts
Principal investigator
Name
136050
0
Dr Nitin Verma
Query!
Address
136050
0
Hobart Eye Surgeons 182 Argyle Street Hobart TAS Australia 7000
Query!
Country
136050
0
Australia
Query!
Phone
136050
0
+61 4 1787 3213
Query!
Fax
136050
0
Query!
Email
136050
0
[email protected]
Query!
Contact person for public queries
Name
136051
0
Tomasz P. Stryjewski
Query!
Address
136051
0
Pykus Therapeutics 1000 Massachusetts Ave, Suite 101, Cambridge, MA 02138
Query!
Country
136051
0
United States of America
Query!
Phone
136051
0
+01 617 394 8960
Query!
Fax
136051
0
Query!
Email
136051
0
[email protected]
Query!
Contact person for scientific queries
Name
136052
0
Tomasz P. Stryjewski
Query!
Address
136052
0
Pykus Therapeutics 1000 Massachusetts Ave, Suite 101, Cambridge, MA 02138
Query!
Country
136052
0
United States of America
Query!
Phone
136052
0
+01 617 394 8960
Query!
Fax
136052
0
Query!
Email
136052
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
This is a pilot/feasibility study which will only generate safety data in a minimal number of subjects.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF